Weed (BUDZ) Free Cash Flow Growth (1y) (2011 - 2026)
Weed (BUDZ) Free Cash Flow Growth (1y) (2011 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.87 Bn | 42.91 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.00 Bn | 39.35 Bn | 2.15 Bn | 134.35% |
| 3 | Zoetis | 31.59 Bn | 29.92 Bn | 1.05 Bn | 17.21% |
| 4 | Takeda Pharmaceutical | 28.63 Bn | 22.83 Bn | 5.10 Bn | -37.45% |
| 5 | United Therapeutics | 22.15 Bn | 19.49 Bn | 683.80 Mn | 58.76% |
| 6 | Viatris | 18.74 Bn | 17.85 Bn | 1.46 Bn | 97.24% |
| 7 | Neurocrine Biosciences | 15.55 Bn | 15.16 Bn | 935.80 Mn | 43.69% |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | 35.56% |
| 9 | Dr Reddys Laboratories | 10.12 Bn | 9.96 Bn | - | - |
| 10 | Weed | 2.88 Mn | 2.88 Mn | - | -1,519.94% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 19.63% |
| Dec 31, 2025 | 6.10% |
| Sep 30, 2025 | 82.70% |
| Jun 30, 2025 | 101.61% |
| Mar 31, 2025 | 59.58% |
| Dec 31, 2024 | 62.50% |
| Sep 30, 2024 | 93.66% |
| Jun 30, 2024 | 22.78% |
| Mar 31, 2024 | 5.05% |
| Dec 31, 2023 | -88.54% |
| Sep 30, 2023 | -136.17% |
| Jun 30, 2023 | 59.27% |
| Mar 31, 2023 | -2.94% |
| Dec 31, 2022 | 47.27% |
| Sep 30, 2022 | -65.24% |
| Jun 30, 2022 | -194.13% |
| Mar 31, 2022 | 38.22% |
| Dec 31, 2021 | -8.54% |
| Sep 30, 2021 | -317.32% |
| Jun 30, 2021 | -29.94% |